Investment analysts at HC Wainwright increased their FY2026 EPS estimates for shares of Corcept Therapeutics in a research note issued on Monday, March 31st. HC Wainwright analyst S. Ramakanth now ...

Piper Sandler analyst David Amsellem raised the firm’s price target on Corcept Therapeutics (CORT) to $131 from $128 and keeps an Overweight ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian ...

The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

Three other Bay Area companies — Mirum Therapeutics Inc. (Nasdaq: MIRM), Soleno Therapeutics Inc. (Nasdaq: SLNO) and Exelixis ...

Highlights,Corient Private Wealth LLC and other firms established or expanded positions in Corcept Therapeutics during the ...

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) hit a new 52-week high during trading on Tuesday after ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Learn more about whether Corcept Therapeutics Incorporated or Zoetis Inc. is a better investment based on AAII's A+ Investor ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...